Biogen Inc.

General ticker "BIIB" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $26.3B (TTM average)

Biogen Inc. does not follow the US Stock Market performance with the rate: -7.4%.

Estimated limits based on current volatility of 1.9%: low 115.98$, high 120.50$

Factors to consider:

  • Company included in S&P500 list
  • Company included in NASDAQ-100 index
  • US accounted for 1.7% of revenue in the fiscal year ended 2024-12-31
  • Earnings for 3 months up through Q1 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [127.71$, 201.46$]
  • 2025-12-31 to 2026-12-31 estimated range: [132.32$, 206.61$]

Financial Metrics affecting the BIIB estimates:

  • Positive: Operating cash flow per share per price, % of 12.76 > 12.73
  • Positive: Non-GAAP EPS, $ of 16.47 > 2.19
  • Positive: 2.69 < Return on assets ratio (scaled to [-100,100]) of 5.50
  • Positive: Interest expense per share, $ of 0 <= 0
  • Negative: Industry earnings per price (median), % of -27.42 <= 0
  • Positive: Inventory ratio change, % of -0.15 <= 0
  • Positive: 43.26 < Shareholder equity ratio, % of 59.60 <= 63.75
  • Positive: Operating profit margin, % of 54.06 > 18.46
  • Negative: Investing cash flow per share, $ of -5.49 <= -3.20

Similar symbols

Short-term BIIB quotes

2025-03-282025-03-312025-04-012025-04-022025-04-032025-04-042025-04-072025-04-082025-04-092025-04-102025-04-112025-04-142025-04-152025-04-162025-04-172025-04-212025-04-222025-04-232025-04-242025-04-252025-04-282025-04-292025-04-302025-05-012025-05-022025-05-052025-05-062025-05-072025-05-082025-05-09110115120125130135140
Price $

Long-term BIIB plot with estimates

100150200250300350400450Jul 2023Jan 2024Jul 2024Jan 2025Jul 2025Jan 2026Jul 2026Jan 2027024
BIIBS&P500Health CareNon-GAAP EPS EstimateNon-GAAP EPS ActualPrice $Non-GAAP EPS $

Financial data

YTD 2022-12-31 2023-12-31 2024-12-31
Operating Revenue $10,173.40MM $9,835.60MM $9,675.90MM
Operating Expenses $7,853.20MM $7,738.30MM $4,445.50MM
Operating Income $2,320.20MM $2,097.30MM $5,230.40MM
Non-Operating Income $1,271.60MM $-800.50MM $-3,324.40MM
Interest Expense $246.60MM $246.90MM $0.00MM
R&D Expense $2,231.10MM $2,702.60MM $2,041.80MM
Income(Loss) $3,591.80MM $1,296.80MM $1,906.00MM
Taxes $632.80MM $135.30MM $273.80MM
Other Income(Loss) $2.60MM $0.00MM $0.00MM
Profit(Loss)* $3,046.90MM $1,161.10MM $1,632.20MM
Stockholders Equity $13,397.90MM $14,799.40MM $16,716.00MM
Inventory $1,344.40MM $2,527.40MM $2,460.50MM
Assets $24,554.10MM $26,844.80MM $28,049.30MM
Operating Cash Flow $1,384.30MM $1,547.20MM $2,875.50MM
Capital expenditure $243.20MM $311.40MM $359.80MM
Investing Cash Flow $1,576.60MM $-4,101.00MM $-799.20MM
Financing Cash Flow $-1,759.70MM $149.30MM $-683.50MM
Earnings Per Share** $20.97 $8.02 $11.20

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.